FDA warns Novo Nordisk of potential unreported GLP-1 side effects
The Food and Drug Administration issued a warning letter to Novo Nordisk — the maker of Ozempic and…
Novo Nordisk warned by FDA for failure to report drug side effects
Novo Nordisk received a warning from the U.S. Food and Drug Administration for failing to report suspected incidents…
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
New, lower list price of $675 per month across Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, addresses…